Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) - Trial NCT03888729
Access comprehensive clinical trial information for NCT03888729 through Pure Global AI's free database. This Phase 4 trial is sponsored by Partners in Health and is currently status unknown. The study focuses on Hepatitis C, Chronic. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Partners in Health
Timeline & Enrollment
Phase 4
Aug 26, 2019
Mar 01, 2020
Primary Outcome
Proportion of participants with sustained viral response 12 weeks after discontinuation of study treatment (SVR12),Proportion of patients treated with SOF/VEL FDC and SOF/VEL/VOX FDC with a new grade 3 or 4 adverse event as defined by the DAIDS Scales or with premature study drug discontinuation due to an adverse event
Summary
The main purpose of the study is to determine the antiviral efficacy and evaluate the safety
 and tolerability of sofosbuvir/ velpatasvir (SOF/VEL) and sofosbuvir/ velpatasvir/
 voxilaprevir (SOF/VEL/VOX) used to treat individuals with chronic hepatitis C virus infection
 in Rwanda adults.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03888729
Non-Device Trial